Letters

;

Letter in support of ensuring copay assistance counts & reining in unscrupulous prescription drug practices

Apr 28, 2023

We strongly support your bipartisan leadership in taking action to address some of the abusive practices Pharmacy Benefit Managers (PBMs) engage in that hinder patient access and the affordability of prescription drugs. While most people think insurers make the majority of decisions regarding health coverage and affordability, when it comes to prescription drugs, it is PBMs that drive many of the decisions as to what medications a beneficiary can access and how much they pay for them.

read more

ABAC letter on the importance of federal programs and funding for ending HIV in the United States

Mar 6, 2023

AIDS Budget and Appropriations Coalition cochairs the HIV+Hepatitis Policy Institute, The AIDS Institute, NASTAD, and AIDS United wrote to the House Appropriations and Senate Appropriations Committees: “While we still do not have a cure or a vaccine, we have the science and tools to eventually end HIV in the U.S. through science-based prevention & treatment progs. However, public health progs across the country must have the sufficient funding and proper policies in place.”

read more

Letter in support for Utah SB 184, Prescription Cost Amendments

Feb 9, 2023

We strongly support SB 184, Prescription Cost Amendments, which would require health insurers to accept and count payments made on behalf of patients towards deductibles and out-of-pocket maximums. We thank you for holding a hearing on this important issue and ask that you consider and pass the bill.

read more

Letter on MassHealth coverage of long-acting injectable PrEP

Jan 9, 2023

A number of Massachusetts-based providers, community-based organizations and clinical sites joined us in writing to you in August 2022 to express our concern that MassHealth had not yet added cabotegravir, a new long-acting injectable form of pre-exposure prophylaxis (PrEP) to prevent HIV, to its formulary, and to urge MassHealth to make sure it is available without any barriers to access, such as utilization management or prior authorization requirements. (A copy of the August letter is attached.)

read more

Patient groups letter urging the Biden administration to oppose extending the TRIPS waiver

Dec 2, 2022

On behalf of patients battling illnesses such as cancer, HIV, diabetes, genetic disorders, and antibiotic-resistant infections, we write to convey our profound opposition to recent actions supported by the Biden administration regarding intellectual property (IP) protections and express our concerns with potential actions that may further erode IP protections that are necessary to produce lifesaving medicines.

read more

Search

Categories

Tags

ACA Appropriations Biden administration CDC co-pay accumulators Congress copay copay accumulator Copay accumulators Copay assistance Cost-sharing COVID-19 Drug Pricing FDA Gay men healthcare Hepatitis Hepatitis B hepatitis C Hepatitis Prevention HHS HIV HIV Prevention Insurers Medicaid medicare Medicare Part D NAIC NIH PBM PBMs PrEP Prescription Drugs Private Insurance Ryan White Program state STDs Syringe services Testing transparency Treatment Trump administration women

Recent Testimony, Letters, Comments

Pin It on Pinterest